
Matthew Baker, MD, MS, discusses INDIGO data showing obexelimab lowered cumulative glucocorticoid toxicity in IgG4-related disease at ACR 2026.

Associate Professor of Medicine and Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University